Exploring the clinical effect of gemcitabine combined with cisplatin as neoadjuvant chemotherapy in the treatment of resectable gallbladder cancer
Objective:To investigate the therapeutic effect of the gemcitabine combined with cisplatin as a neoad-juvant chemotherapy(NACT)regimen in patients with resectable gallbladder cancer(GBC).Methods:A retro-spective analysis was conducted on the data of 59 patients diagnosed with GBC through histological or cytological ex-amination via biopsy or laparoscopic guidance.Patients who received gemcitabine combined with cisplatin as NACT were classified as the NACT group(26 cases),while those who did not receive NACT were classified as the No-NACT group(33 cases).Tumor prognostic factor levels at admission and one week postoperatively,surgical out-comes,overall survival(OS),and progression-free survival(PFS)were compared between the two groups.Results:One week postoperatively,the mean CA19-9 and neutrophil-to-lymphocyte ratio(NLR)levels in the NACT group were significantly lower than those in the No-NACT group(P＜0.05).There were no statistically sig-nificant differences between the NACT and No-NACT groups in terms of complication rates(19.23％vs 24.24％)or R0 resection rates(92.31％vs 72.73％)(P＞0.05).The proportion of patients with tumor size＜3 cm in the NACT group was 53.85％,significantly lower than the 24.24％in the No-NACT group(P＜0.05).Both OS and PFS in the NACT group were significantly longer compared to the No-NACT group(P＜0.05).Conclusion:The NACT regimen of gemcitabine combined with cisplatin can reduce unfavorable tumor prognostic factors levels,pro-long OS and PFS,and improve prognosis of GBC patients,with a high safety profile.
万方数据
维普
